Veradermics Hair Loss Trial Success Spurs Funding Plans For VDPHL01

Simply Wall St.04-29

Veradermics (NYSE:MANE) reported positive topline data from its pivotal Phase 2/3 trial of VDPHL01, an investigational non-hormonal oral treatment for pattern hair loss. The company framed VDPHL01 as ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2631058274?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-04-29 01:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631058274","market":"hk","top_or_hot":-1,"title":"Veradermics Hair Loss Trial Success Spurs Funding Plans For VDPHL01","media":"Simply Wall St.","content":"<div>\n<p>Veradermics (NYSE:MANE) reported positive topline data from its pivotal Phase 2/3 trial of VDPHL01, an investigational non-hormonal oral treatment for pattern hair loss. The company framed VDPHL01 as ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-trial-success-spurs-funding-plans-for\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veradermics Hair Loss Trial Success Spurs Funding Plans For VDPHL01</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeradermics Hair Loss Trial Success Spurs Funding Plans For VDPHL01\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-29 01:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-trial-success-spurs-funding-plans-for><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Veradermics (NYSE:MANE) reported positive topline data from its pivotal Phase 2/3 trial of VDPHL01, an investigational non-hormonal oral treatment for pattern hair loss. The company framed VDPHL01 as ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-trial-success-spurs-funding-plans-for\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MANE","symbol_name":"Veradermics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-trial-success-spurs-funding-plans-for","article_id":"2631058274","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mane/veradermics/news/veradermics-hair-loss-trial-success-spurs-funding-plans-for","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2631058274","pubTimestamp":1777395801,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Veradermics (NYSE:MANE) reported positive topline data from its pivotal Phase 2/3 trial of VDPHL01, an investigational non-hormonal oral treatment for pattern hair loss.\nThe company framed VDPHL01 as a potential first in class oral option that could lead to the first FDA approval for a non-hormonal hair loss pill in nearly 30 years.\nFollowing the clinical update, Veradermics launched a proposed public offering tied to this stage of clinical and corporate progress.\n\nVeradermics focuses on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MANE":"Veradermics, Inc.","BK4007":"制药"},"translate_title":"Veradermics脱发试验的成功刺激了VDPHL01的资助计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MANE":1.5},"content_text":"Veradermics (NYSE:MANE) reported positive topline data from its pivotal Phase 2/3 trial of VDPHL01, an investigational non-hormonal oral treatment for pattern hair loss. The company framed VDPHL01 as a potential first in class oral option that could lead to the first FDA approval for a non-hormonal hair loss pill in nearly 30 years. Following the clinical update, Veradermics launched a proposed public offering tied to this stage of clinical and corporate progress.  Veradermics focuses on dermatology treatments, and VDPHL01 sits at the center of its effort to address pattern hair loss with a non-hormonal oral medicine. Hair loss remains a large consumer and medical category, with existing options often centered on topical products or hormonal agents. In that context, news around a potential first in class oral therapy attracts attention from both healthcare and consumer oriented investors. The planned public offering suggests that Veradermics is aligning its capital plans with this clinical milestone. For readers, key questions now focus on how the company manages regulatory interactions, further data releases, and potential commercialization plans if VDPHL01 proceeds to an FDA review. Stay updated on the most important news stories for Veradermics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Veradermics. NYSE:MANE Earnings & Revenue Growth as at Apr 2026 📰 Beyond the headline: 3 risks and 1 thing going right for Veradermics that every investor should see. For Veradermics, positive topline data from the Phase 2/3 trial of VDPHL01 and the follow on equity offering are tightly linked. The trial met its primary and key secondary endpoints with statistically significant results in 519 participants, and the company describes the safety profile as favorable with no serious treatment related adverse events. Positioning VDPHL01 as a potential first in class, non hormonal oral option for pattern hair loss sets Veradermics against incumbents such as topical minoxidil, prescription oral finasteride, and broader hair loss brands often backed by companies like Johnson & Johnson, Organon, or consumer platforms that already market hair loss products. That context points to a large addressable market if VDPHL01 progresses through late stage development and regulatory review. AdvertisementThe Risks and Rewards Investors Should Consider  ⚠️ Veradermics currently reports less than US$1m in revenue, so the business remains early stage and dependent on external funding. ⚠️ The share price has been highly volatile over the past 3 months, which can increase the risk of sharp moves around news or further capital raises. 🎁 Positive Phase 2/3 data for VDPHL01 in a large hair loss market could, if the program advances, open up a new oral treatment category that differs from hormonal approaches. 🎁 The company is already moving to raise capital through a follow on offering and related warrant sales, which, if completed, could support the next steps in VDPHL01 development.  What To Watch Going Forward Investors will want to track how regulators respond to the Phase 2/3 dataset for VDPHL01, including any guidance on further trials or filing requirements. The terms, pricing, and ultimate size of the 3,350,000 share offering and associated pre funded warrants will also matter, because they shape dilution and available cash for clinical and potential commercial work. Attention will likely remain on future data updates, expansion into female pattern hair loss, and any partnering or commercialization plans, especially as larger players in dermatology and consumer health such as Pfizer, Johnson & Johnson, or Organon already participate in the broader hair loss category. To ensure you're always in the loop on how the latest news impacts the investment narrative for Veradermics, head to the\n community page for Veradermics to never miss an update on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2631058274","isCrawlerRequest":true}